The Number of Genomic Copies at the 16p11.2 Locus Modulates Language, Verbal Memory, and Inhibition. by Hippolyte, L. et al.
iological
sychiatryArchival Report BPThe Number of Genomic Copies at the 16p11.2
Locus Modulates Language, Verbal Memory,
and Inhibition
Loyse Hippolyte, Anne M. Maillard, Borja Rodriguez-Herreros, Aurélie Pain, Sandra Martin-Brevet,
Carina Ferrari, Philippe Conus, Aurélien Macé, Nouchine Hadjikhani, Andres Metspalu,
Anu Reigo, Anneli Kolk, Katrin Männik, Mandy Barker, Bertrand Isidor, Cédric Le Caignec,
Cyril Mignot, Laurence Schneider, Laurent Mottron, Boris Keren, Albert David, Martine
Doco-Fenzy, Marion Gérard, Raphael Bernier, Robin P. Goin-Kochel, Ellen Hanson,
LeeAnne Green Snyder, 16p11.2 European Consortium, Simons Variation in Individuals Project
Consortium, Franck Ramus, Jacques S. Beckmann, Bogdan Draganski, Alexandre Reymond, and
Sébastien JacquemontABSTRACT
BACKGROUND: Deletions and duplications of the 16p11.2 BP4-BP5 locus are prevalent copy number variations
(CNVs), highly associated with autism spectrum disorder and schizophrenia. Beyond language and global cognition,
neuropsychological assessments of these two CNVs have not yet been reported.
METHODS: This study investigates the relationship between the number of genomic copies at the 16p11.2 locus
and cognitive domains assessed in 62 deletion carriers, 44 duplication carriers, and 71 intrafamilial control subjects.
RESULTS: IQ is decreased in deletion and duplication carriers, but we demonstrate contrasting cognitive proﬁles in
these reciprocal CNVs. Deletion carriers present with severe impairments of phonology and of inhibition skills beyond
what is expected for their IQ level. In contrast, for verbal memory and phonology, the data may suggest that
duplication carriers outperform intrafamilial control subjects with the same IQ level. This ﬁnding is reminiscent of
special isolated skills as well as contrasting language performance observed in autism spectrum disorder. Some
domains, such as visuospatial and working memory, are unaffected by the 16p11.2 locus beyond the effect of
decreased IQ. Neuroimaging analyses reveal that measures of inhibition covary with neuroanatomic structures
previously identiﬁed as sensitive to 16p11.2 CNVs.
CONCLUSIONS: The simultaneous study of reciprocal CNVs suggests that the 16p11.2 genomic locus modulates
speciﬁc cognitive skills according to the number of genomic copies. Further research is warranted to replicate these
ﬁndings and elucidate the molecular mechanisms modulating these cognitive performances.
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4–5 (BP4-BP5) region are among the most frequent causes of
neurodevelopmental and neuropsychiatric disorders (1–5).
Although copy number variations (CNVs) are equally and
frequently present in autism spectrum disorder (ASD) cohorts,
only duplications are associated with schizophrenia (4). Recent
studies in 16p11.2 CNV carriers demonstrated altered global
cognition in deletion carriers and duplication carriers showing,
respectively, up to 24-point and 15-point decreases in full-
scale intelligence quotient (FSIQ) compared with intrafamilial
control subjects (1,6,7). Regarding cognitive domains, language
impairment in deletion carriers was reported in several case
series (8,9), and speciﬁc assessments showed below-average
performance in comprehension, expression, and reading skills
with a 71% rate of speech and language disorder as deﬁned in& 2016 Society of B
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SEE COMMENTARDSM-IV-TR (6,10). To our knowledge, performance of duplica-
tion carriers in speciﬁc cognitive domains has not yet been
studied.
Most studies of CNVs investigated deletions and duplica-
tions separately using a case-control design; however, the
simultaneous assessment of reciprocal CNVs of the same
genomic region provides a unique opportunity to study how
the number of genomic copies (one, two, or three) may
modulate clinical phenotypes and endophenotypes. We and
other authors previously showed that body mass index
inversely correlates to the number of genomic copies at the
16p11.2 locus (1,9,11–13). The number of genomic copies is
also negatively correlated with global brain volume (14) and
associated with neuroanatomic structures involved in reward,
language, and social-cognition circuits (15).iological Psychiatry. This is an open access article under the
D license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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16p11.2 Copy Number Variation and Cognition
Biological
PsychiatryWe hypothesized that speciﬁc cognitive skills correlate with
the number of genomic copies of the 16p11.2 region beyond
the decrease in IQ observed in both types of CNV carriers. We
also explored whether this relationship is mediated by
changes in brain structure. Our ﬁndings suggest that this
locus modulates speciﬁc cognitive domains resulting in
impaired as well as preserved or possibly enhanced skills
relative to IQ in carriers of reciprocal CNVs. Neuroimaging
analysis suggests that brain regions previously identiﬁed as
correlating with the number of genomic copies are associated
with alterations in executive functions in 16p11.2 CNV carriers.
METHODS AND MATERIALS
Participants
European Cohort. Participants were taking part in a larger
research project on CNVs at the 16p11.2 locus with the aim of
phenotyping a European cohort of 16p11.2 rearrangement
carriers. Included in our analyses were 62 deletion carriers (37
probands/25 nonproband carriers), 44 duplication carriers (21
probands/23 nonproband carriers), and 71 intrafamilial control
subjects (Table 1). Nonproband carriers are deﬁned as rela-
tives who carry the CNV identiﬁed through family cascade
testing but who were not referred for a neurodevelopmental
disorder. Inclusion criteria included presence of a recurrent
16p11.2 deletion or duplication comprising the BP4–BP5
region (29.6–30.2 Mb according to the human genome build
GRCh37/hg19). Control subjects were noncarriers in the same
families. Individuals ,3 years old were excluded from the
analyses. Also, 24 participants who were unable to perform
the cognitive tasks because of low cognitive functioning were
excluded (Supplemental Table S1).
Additional deleterious CNVs were identiﬁed in one deletion
carrier and ﬁve duplication carriers (Supplemental Table S2).
These participants were not removed from the analyses, but
their potentially confounding effects were taken into accountTable 1. Sample Characteristics
Deletion
Carriers
(n = 62)
Control
Subjects
(n = 71)
Duplication
Carriers
(n = 44)
Age, Years,
Mean 6 SD (range)
21.7 6 15.4a
(4.8–59)
34 6 15.3
(3.3–62)
28.9 6 16.8
(3.3–65)
Sex, M/F 35/27 31/40 25/19
Handedness, R/L/U 44/11/7 62/6/3 33/9/2
Inheritance, De novo/In/U 16/26/20 — 8/15/21
Kinship, Proband/
Nonproband Carriers
37/25 — 21/23
ASD, n 3 0 5
Schizophrenia, n 0 0 0
FSIQ, Mean 6 SD 72 6 13.6b 98 6 15 75 6 17.8b
NVIQ, Mean 6 SD 78 6 11.7b 99 6 15.5 76 6 15.3b
ASD, autism spectrum disorder; F, female; FSIQ, full-scale intelli-
gence quotient (standard score); In, inherited; L, left; M, male; NVIQ,
nonverbal intelligence quotient (standard score); R, right; U, unknown/
undeﬁned.
aSigniﬁcantly different from the control group, linear model,
p , .0001.
bSigniﬁcantly different from the control group, linear mixed model,
all p , .0001.
130 Biological Psychiatry July 15, 2016; 80:129–139 www.sobp.org/join a subanalysis. Deleterious CNVs were deﬁned as 1) CNVs
associated with a known recurrent genomic disorder, 2)
CNVs encompassing a published critical genomic region or
disrupting a gene that is a known cause of neurodevelop-
mental disorders, or 3) rare (,1/1000) and large (.500
kb) CNVs.
The study was reviewed and approved by the local ethics
committee, and signed consent forms were obtained from
participants or legal representatives before investigation.
Participants were assessed at the Lausanne University Hos-
pital, Switzerland. Of the proband carriers, .87% were
referred to the study by the clinical geneticist who had initially
established the genetic diagnosis in the context of a neuro-
developmental disorder. Seven probands (four duplication
carriers and three deletion carriers) were identiﬁed in the
population biobank of Estonia as previously described (16),
and one duplication carrier was referred for psychiatric prob-
lems. All but four participants (n = 2 Asian descent and n = 2
African descent) were of European descent.
Simons Variation in Individuals Project Cohort. For
replication analyses on language, we used data from
the Simons Variation in Individuals Project (VIP) cohort
(http://sfari.org/resources/simons-vip), which aims at pheno-
typing carriers with a 16p11.2 BP4–BP5 rearrangement
(Supplemental Methods and Materials) (6,7).
Cognitive Assessment
Trained neuropsychologists performed all cognitive assess-
ments. Participants underwent age-appropriate and develop-
mentally appropriate neuropsychological tests assessing
overall cognitive functioning, ﬁne motor skills, language,
memory, and executive functions. All Z scores were derived
from standardized scores based on population norms pro-
vided by the testing manuals. When normative data were
unavailable, we used raw scores that were adjusted for age
and sex when appropriate. We speciﬁed the tasks where the
latter procedure was applied. We used the following psycho-
metric tests.
Overall Cognitive Functioning. The Wechsler Intelligence
Scales or Wechsler Abbreviated Scale of Intelligence (17–20)
was used to obtain FSIQ, nonverbal intelligence quotient
(NVIQ), and verbal intelligence quotient (VIQ) when available.
The FSIQ, NVIQ, and VIQ were estimated using the Differential
Ability Scales–2nd Edition (21) or the Wechsler Abbreviated
Scale of Intelligence in the VIP cohort.
Fine Motor Skills. The Purdue Pegboard test (22) ($5 years
old) assessed four conditions: dominant hand, nondominant
hand, bimanual, and assembly. Z scores were used as
dependent variables.
Language. Phonological skills were assessed with nonword
repetition ($5 years old), oromotor sequences ($3 years old),
and phonological processing ($3 years old) from the Dev-
elopmental Neuropsychological Assessment battery (23).
Age-adjusted raw scores were the dependent variables.urnal
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PsychiatryParticipants $16 years old performed a sentence repetition
task including low-frequency words. The score was the
number of correct repetitions adjusted for age. Phonology in
the VIP cohort was measured by the nonword repetition
subtest ($4 years old) from the Comprehensive Test of
Phonological Processing (24), which is similar to the Devel-
opmental Neuropsychological Assessment nonword repetition
task. Age-adjusted raw score was the dependent variable.
Lexical skills were assessed with the Wechsler Vocabulary
subtest (word deﬁnition, $4 years old) and the Peabody
Picture Vocabulary Test Revised (25) (word comprehension,
$3 years old), semantic ﬂuency (animal, $3 years old), and
phonemic ﬂuency (letter M, $5 years old). For word compre-
hension and word deﬁnition tasks, Z score were used as
dependent variables, and age-adjusted raw scores were used
for verbal ﬂuencies.
Comprehension and verbal skills were assessed by selecting
24 items from the Test for Reception of Grammar 2 (26), syntax
comprehension ($15 years old), and the Wechsler Similarity
subtest ($7 years old). Z score (similarity) and age-adjusted raw
scores (syntax) were used as dependent variables. Written
language ($12 years old) was assessed through a reading task
(PC Robbery) (27) and a spelling task (Collective Spelling
Tracking) (28). Reading ﬂuency and reading comprehension
Z scores were used as dependent variables; age-adjusted and
sex-adjusted total raw scores were used for the spelling task.
Memory. Verbal short-term memory was assessed using the
forward digit span task ($6 years old) (18,19). The total age-
adjusted raw score was used as the dependent variable.
Verbal long-term memory was assessed using the California
Verbal Learning Task ($17 years old) (29). Two Z scores were
used as dependent variables: number of words correctly
recalled across all ﬁve learning trials (encoding) and number
of words recalled after a 20-minute delay (delayed recall).
Visuospatial short-term memory was assessed using the
forward spatial span task ($6 years old) (30,31). The total age-
adjusted raw score was used as the dependent variable.
Visuospatial long-term memory was assessed with the Rey-
Osterrieth Complex Figure test ($5 years old) (32). For imme-
diate and delayed (20 minutes) recalls, Z scores were used.
Executive Functions. Working memory ($6 years old) was
assessed using the backward digit span (18,19) and the
backward spatial span (30,31) tasks. The total age-adjusted
raw scores were used as dependent variables. Planning skills
were assessed with the Tower of London test ($7 years old)
(33). Z scores for total correct score and total move score were
used. The Stroop task ($8 years old) (34) was used to assess
verbal inhibition. A computerized version of the go/no-go task
($7 years old) (35) was used to assess motor inhibition. In both
tasks, Z scores for response time and number of errors
adjusted for age were used as dependent variables.
General Psychiatric and Autism Assessments
Experienced licensed psychologists and psychiatrists per-
formed the Autism Diagnostic Interview–Revised (36) and
Autism Diagnostic Observation Schedule (37) to establish a
categorical diagnosis in all participants presenting with ASDBiologicalsymptoms. All adult carriers underwent the Diagnostic Inter-
view for Genetic Studies to screen for major psychiatric
disorders (38).
Magnetic Resonance Imaging: Data Acquisition and
Processing
We used structural magnetic resonance imaging data acquired
for a previously published study (Supplemental Methods and
Materials and Supplemental Table S3) (14).Statistical Analyses
Neuropsychological Data Analyses. Variables derived
from normative data were converted into Z scores for each
participant (mean = 0; SD = 1) (Supplemental Methods and
Materials). Raw scores of variables without available normative
data were systematically adjusted for age and sex where
appropriate. We performed either linear or generalized regres-
sion analyses depending on data distribution. Cognitive
measures were the dependent variables.
To investigate the effect of CNV on cognition, we used linear
models including the following ordinal variables: deletion = 1,
control = 2, duplication = 3. For contrasts between groups, we
used post hoc t tests. Appropriate linear mixed models or
generalized linear mixed models were performed taking the
variable “family” as a random factor to account for correlated
measures within family. We also included in the statistical
design IQ, sex, and their interactions with the number of
genomic copies to control for the effects of these variables.
These additional covariates were kept in the ﬁnal models only
when the effect was signiﬁcant. Results of noncarrier partic-
ipants from deletion or duplication families were pooled, as
they did not differ in age, sex, and cognitive performances.
Selected models, estimates, and uncorrected p values are
reported in Table 2 and Supplemental Tables S4–S6.
Multiple testing correction is detailed in Supplemental
Methods and Materials. It takes into account all 34 cognitive
tests, their level of intercorrelation, and the two post hoc
contrasts (deletion carriers vs. control subjects and duplication
carriers vs. control subjects). Uncorrected p values # .001 are
considered signiﬁcant, and trends are deﬁned as .001 , p
values # .05. Statistical analyses were conducted using R
3.0.2 (The R Project for Statistical Computing; http://www.
R-project.org/).
Brain Structure and Behavior Correlation Analyses.
We tested whether the effects of CNVs on cognitive meas-
ures are mediated by changes observed in brain anatomy.
Therefore, only cognitive measures (Z scores and raw scores
adjusted for age and IQ) with signiﬁcant differences between
CNV carriers and intrafamilial control subjects were subse-
quently used for regression analysis with brain anatomy. The
statistical design also included age, sex, and total intracranial
volume as regressors. Voxel-based statistical analysis of the
gray matter (GM) regional changes was assessed by creating
voxelwise statistical parametric maps for the whole extent of
the search volume using the general linear model and random
ﬁeld theory (38). Given that the number of genomic copies
negatively correlates with GM volume in language andPsychiatry July 15, 2016; 80:129–139 www.sobp.org/journal 131
Table 2. Group Contrasts and Copy Number Variation Effect for Cognitive Measures Adjusting for IQ
Deletion Carriers vs.
Duplication Carriers
Deletion Carriers vs.
Control Subjects
Duplication Carriers vs.
Control Subjects
Copy Number
Variation
Cognitive Variables Estimatea (SE) p Value Estimateb (SE) p Value Estimateb (SE) p Value Estimate p Value
Language
Phonological skillsc
Nonword repetition (age-adjusted)d 7.27 (1.88) .0002e 210.96 (1.89) 5.2e-08e 23.68 (2.08) .078 4.1 9.9e-05e
Oromotor sequences (age-adjusted)d 10.44 (2.69) .001e 213.1 (2.68) 2.7e-06e 22.68 (2.9) .36 5.6 8e-05e
Sentence repetition (age-adjusted)d .76 (.24) .0015 2.94 (.21) 1.1e-05e 2.17 (.26) .5 .46 .0001e
Lexical skillsf
Word deﬁnition (Z score) .48 (.19) .01 2.81 (.19) 2.1e-05e 2.33 (.2) .1 .27 .0047
Comprehension and verbal skillsg
Written languageh
Reading ﬂuency (Z score) 1.7 (.52) .0015 22.1 (.48) 4.1e-05e 2.4 (.5) .44 .92 .0009e
Memory
Verbal short-term memory
Forward digit span (age-adjusted)d 1.54 (.4) .0002e 21.32 (.48) .003 .21 (.45) .64 .78 .0002e
Verbal long-term memory
CVLT encoding (sex-adjusted Z score) 1.36 (.29) 7.2e-06e 2.22 (.28) .43 1.14 (.3) .0002e .66 1.6e-05e
CVLT delayed recall (sex-adjusted Z score) 1.35 (.32) 5.9e-05e 2.03 (.31) .92 1.31 (.34) .0001e .64 .0001e
Visuospatial short-term and long-term memoryi
Executive Functions
Working memory and planningj
Inhibitionk
Stroop number of successes (age-adjusted)d .85 (.21) 4e-05e 2.78 (.17) 3e-06e .07 (.2) .72 .46 7.5e-06e
Fine Motor Skillsl
Purdue dominant hand (Z score) .56 (.26) .035 2.97 (.28) .0009e 2.41 (.29) .16 .3 .031
Purdue nondominant hand (Z score) .49 (.23) .03 21.1 (.26) 4.6e-05e 2.59 (.26) .026 .26 .035
CVLT, California Verbal Learning Test.
Linear mixed models were used to account for the correlations of measures within families. When only one family member was included in the
analysis, linear models were performed. Because of space constraints, cognitive variables showing no signiﬁcant effect of copy number variation or no
signiﬁcant group differences (c, f-l; p values corrected) are presented in Supplemental Table S5.
aPositive estimate: Deletion carrier score , duplication carrier score.
bNegative estimate: Deletion carrier or duplication carrier score , control subject score.
cPhonological processing.
dRaw score.
eSigniﬁcant p value (corrected threshold, p = .001).
fWord comprehension, semantic and phonemic ﬂuencies.
gSyntax comprehension and verbal reasoning.
hReading comprehension and spelling.
iForward spatial span and Rey-Osterrieth Complex Figure (immediate and delayed recall).
jBackward digit span, backward spatial span, and Tower of London (total correct and total move scores).
kStroop response time, go/no-go response time, and number of successes.
lPurdue: bimanual and assembly conditions.
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Psychiatryreward-related areas (14), we tested whether the behavioral
deﬁcits were associated with an increase of local GM volume.
Consequently, one-tailed t tests were used to identify the
regions whose volume showed negative correlation with the
cognitive score.
We subsequently estimated the degree of overlap between
brain areas correlating with behavioral scores and the pre-
viously identiﬁed regions sensitive to CNV (15). Clusters
sharing both effects were obtained with a subtraction of the
two statistical maps. We further examined how the number of
genomic copies interacted with the brain-behavior correlation
in these regions, using a multiple linear regression analysis of132 Biological Psychiatry July 15, 2016; 80:129–139 www.sobp.org/jothe summed voxel values for each group. For all whole-brain
analyses, we applied a voxel-level threshold of p , .05 after
familywise error correction for multiple comparisons. Trends
were assessed by using an auxiliary uncorrected voxel thresh-
old of p , .001 (39).RESULTS
Deletion carriers and duplication carriers showed cognitive
impairment (FSIQ = 72 for deletion carriers, FSIQ = 75 for
duplication carriers) compared with intrafamilial control sub-
jects (FSIQ = 98), consistent with a larger study we recentlyurnal
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Psychiatrypublished (Supplemental Table S4) (7). All verbal and non-
verbal subtests from the Wechsler Abbreviated Scale of
Intelligence equally contributed to this IQ deﬁcit
(Supplemental Figure S1). To estimate the effect of the
deletion and the duplication on speciﬁc cognitive domains
beyond their impact on general cognition, we performed all
subsequent analyses adjusting for NVIQ in verbal tasks and
FSIQ otherwise (Table 2 and Supplemental Table S5; see
Supplemental Table S6 for results not adjusted for IQ).
16p.11.2 Locus Modulates Phonology, Written
Language, and Vocabulary
The number of genomic copies positively correlated with
phonology measures such as nonword repetition (p = 9.9e-
05), oromotor sequences (p = 8e-05), and sentence repetition
(p = .0001) as well as a closely related task, reading ﬂuency (p
= .0009). This effect was mainly driven by the deletion carriers,
who performed worse than control subjects and duplication
carriers; these two latter groups did not signiﬁcantly differ
(Figure 1A–C). Word deﬁnition showed a similar trend (p =
.0047) (Table 2). Except for trends, none of the measures
assessing spelling, verbal ﬂuencies, verbal comprehension,
and verbal reasoning were signiﬁcantly affected by the
16p11.2 locus (Supplemental Table S5).
Results from the VIP data set conﬁrmed that the number of
genomic copies correlated with performance in the nonword
repetition task adjusted for NVIQ (p = 9e-6). The effect was
driven by both CNVs, with deletion carriers performing worse
than duplication carriers and intrafamilial control subjects (p =
2.7e-6 and p = .002, respectively) and duplication carriers
outperforming control subjects (p = .016) (Supplemental
Figure S2).
Verbal Short-Term and Long-Term Memory
Processes Are Modulated by the Number of Genomic
Copies
All verbal memory measures correlated positively with the
number of genomic copies. Duplication carriers outperformed
deletion carriers and control subjects in measures of verbal
long-term memory after adjusting for NVIQ (Figure 1D–F).
Scatter plots showing correlations between verbal long-term
memory measures and NVIQ conﬁrmed that duplication
carriers scored higher than control subjects with similar NVIQ
(Supplemental Figure S3). Regarding verbal short-term mem-
ory, deletion carriers scored signiﬁcantly worse than duplica-
tion carriers (p = .0002) and control subjects (trend, p = .003).
The 16p11.2 locus did not signiﬁcantly affect either short-term
or long-term visuospatial memory.16p11.2 Locus Modulates Inhibition Skills But Not
Working Memory and Planning
Motor and verbal inhibition measures positively correlated to
the number of genomic copies (signiﬁcant for verbal inhibition,
trend for motor inhibition) (Figure 1G–I). Deletion carriers who
performed or tended to perform worse than control subjects
and duplication carriers mainly drove this effect (Table 2). We
did not observe any group differences in working memory and
planning skills (Supplemental Table S5).BiologicalFine Motor Skills. Deletion carriers performed worse than
control subjects in Purdue dominant and nondominant hand
conditions, but there were no signiﬁcant differences in the
bimanual and assembly conditions.
Overall Neuropsychological Proﬁle. To illustrate the
neuropsychological proﬁles of deletion and duplication carriers,
we summarized a sample of the cognitive tasks adjusted and
unadjusted for IQ (Figure 2A, B). Carriers’ data were converted
into Z scores relative to the intrafamilial control subjects to
highlight preserved skills (performance similar to controls after
adjusting for IQ), speciﬁc deﬁcits, and enhanced performances
(lower and higher performances than expected for IQ level).
When adjusted for IQ levels (Figure 2A), the cognitive proﬁle of
deletion carriers showed speciﬁc deﬁcits in language and
inhibition domains, whereas there was no speciﬁc impairment
in the proﬁle of duplication carriers. The latter group showed
enhanced performance in verbal long-term memory. When
results were unadjusted for IQ (Figure 2B), both CNV carriers
showed similar decreased performance in several tasks consis-
tent with their overall IQ level (e.g., verbal comprehension,
working memory, planning, visuospatial skills).
ASD Diagnosis and Additional CNVs. We considered
possible confounders including a diagnosis of ASD (three
deletion carriers and ﬁve duplication carriers) or the presence
of additional deleterious CNVs (one deletion carrier and ﬁve
duplication carriers). The analyses performed after excluding
participants with additional CNVs (Supplemental Table S7) and
analyses excluding participants with ASD led to the same results.
We also considered possible bias secondary to ascertainment
for neurodevelopmental disorders, but proband carriers were not
outperformed by nonproband carriers in any of the cognitive
measures (Supplemental Table S8). Finally, the effect of inher-
itance was tested. In the deletion group, performances of de
novo carriers did not differ from performances of the inherited
carriers (Supplemental Table S9).
Correlation With Brain Anatomy. Whole-brain voxel-
based morphometry analysis showed a positive correlation
between GM volume and the verbal inhibition error rate in
bilateral insula and transverse temporal gyri (Figure 3 and
Supplemental Table S10). Subsequent regression analyses
(left cluster, r2 = .14, p = .007; right cluster, r2 = .24, p = .0003)
revealed that the effect was mainly driven by deletion carriers,
who showed the greatest variance (Figure 3B, C). We report a
trend (uncorrected p value , .001 for all the clusters) for
increased GM volume in the left inferior frontal gyrus, bilateral
superior temporal gyri, and bilateral caudate associated with
deﬁcits in two measures related to phonology: nonword
repetition and reading ﬂuency. Measures of memory did not
covary with any brain structure.DISCUSSION
By assessing carriers of deletion and duplication at the
16p11.2 locus and intrafamilial control subjects, our study
characterizes the effect of this genomic region on severalPsychiatry July 15, 2016; 80:129–139 www.sobp.org/journal 133
Figure 1. Copy number variation and group comparisons on language, memory, and executive measures. Box plots represent language measures of
phonology (A–C), memory (D–F), and executive functions (G–I) in deletion carriers, duplication carriers, and intrafamilial control subjects. Higher scores
translate into better performance except for panel (I), where better performance is represented by a shorter response time. The bold line shows the median,
and the bottom and top of the box show the 25th (quartile 1 [Q1]) and the 75th (quartile 3 [Q3]) percentile, respectively. The upper whisker ends at highest
observed data value within the span from Q3 to Q3 1 1.5 times the interquartile range (Q3–Q1), and lower whisker ends at lowest observed data value within
the span for Q1 to Q1 2 (1.5 * interquartile range). Circles are outliers. Copy number variation effect (one, two, or three copies) and group contrasts are
estimated using a linear mixed model to account for correlated measures within families (A, B, D, G, H, I) and a linear model when only one family member is
included in the analysis (E, F). A nonlinear model was required for panels (C, G, H). We present Z scores when normative data are available in the testing
manual. Otherwise, we present raw scores adjusted for age and sex when appropriate. All scores are adjusted for IQ except for panel (I). Signiﬁcant post hoc
group comparisons (p-corrected threshold = .001) are represented by solid lines with exact p values above, and trends are represented by dashed lines with
exact p values above. CTRL, intrafamilial control subjects; DEL, deletion carriers; DUP, duplication carriers.
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is decreased in both CNVs, speciﬁc cognitive functions
including verbal memory, executive functions, and phonolog-
ical skills show a positive correlation with the number of
genomic copies. The data suggest that duplication carriers
outperform intrafamilial control subjects with the same IQ for
measures of verbal memory and phonology.
A recent study (40) comparing recurrent reciprocal CNVs failed
to identify any correlations between cognitive functions and copy
number state at the 16p11.2 BP4–BP5 and 15q11.2 BP1–BP2
loci. Either the small sample size (n = 7 for 16p11.2 deletion
carriers and duplication carriers, respectively) or the small effect
size (for 15q11.2 BP1–BP2) could explain the lack of signiﬁcant
correlations between cognitive traits and copy number state.134 Biological Psychiatry July 15, 2016; 80:129–139 www.sobp.org/joAlthough linear models show that the number of genomic
copies correlates with performance in several cognitive
domains, our study was underpowered to demonstrate for-
mally that deletion carriers perform worse than control sub-
jects and control subjects perform worse than duplication
carriers for a speciﬁc function. However, the results are
suggestive of such a phenomenon; our analysis of phonologic
skills in a larger independent data set (VIP) supports the
hypothesis that, similar to other complex traits such as body
mass index or brain anatomy, cognitive performances may
covary with molecular mechanisms. Recent ﬁndings on
16p11.2 CNVs mouse models show enhanced memory skills
on a recognition task in duplicated mice compared to wild-
type animals (41). Memory processes have also been linked tournal
Figure 2. Neuropsychological proﬁle in 16p11.2 deletion carriers and
duplication carriers. IQ-adjusted (A) and IQ-unadjusted (B) neuropsycholo-
gical proﬁle of deletion carriers and duplication carriers. The y axis represents
mean cognitive residual scores for deletion carriers (red circles) and duplica-
tion carriers (blue squares) converted into Z scores relative to the intrafamilial
control subjects (black dashed line). Error bars represent SEM. When
appropriate, scores are adjusted for age and sex. The x axis lists one task
per subdomain with the most complete data set: NW repetition (nonword
repetition), Word def (word deﬁnition), Word compr (word comprehension), V
short-term (verbal short-term memory), S short-term (spatial short-term
memory), V long-term (verbal long-term memory), S long-term (spatial long-
term memory), VW memory (verbal working memory), Planning, V inhibition
(verbal inhibition number of success), M inhibition (motor inhibition number of
success), and FSIQ (full-scale intelligence quotient). CTRL, intrafamilial
control subjects; DEL, deletion carriers; DUP, duplication carriers.
Figure 3. Brain structure-behavior correlation analysis between verbal
inhibition score and gray matter (GM) map. (A) Spatial overlap between
negative linear correlation with Stroop score (red) and the neuroanatomic
structures previously identiﬁed as correlating to the number of genomic
copies of the 16p11.2 locus (15). Overlapping clusters are represented in
orange. Maps are thresholded at the p , .05 familywise error corrected level.
Panels (B, C) are scatter plots showing the linear correlation between GM
volume and the Stroop performance at the clusters located in the left insula
(B) and in the right temporal gyri (C) in panel (A). Both panels include the
regression line, correlation coefﬁcient, and p value for each cohort.
CTRL, intrafamilial control subjects; DEL, deletion carriers; DUP, duplication
carriers.
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Psychiatrymechanisms regulating long-term synaptic potentiation and
depression. These synaptic mechanisms require bursts of
local protein synthesis during training and stimulation (42).
Both mammalian target of rapamycin signaling and MAPK3
signaling regulate local synaptic protein synthesis, which
modulates memory performances in murine models (43,44).
The expression levels of MAPK3, which maps within the BP4–
BP5 interval, and of mammalian target of rapamycin pathway
members are signiﬁcantly altered in 16p11.2 CNV carriers (45).
These are good candidate genes underlying or mediating theBiological Psychiatry July 15, 2016; 80:129–139 www.sobp.org/journal 135
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Psychiatrycorrelation between genomic copy number and memory
performances.
Deletion and duplication are strongly and equally associ-
ated with ASD, but our study shows that their cognitive
proﬁles seem to be distinct, highlighting the heterogeneity of
ASD. Our results are consistent with the results of D’Angelo
et al. (7), who observed that the duplication is associated with
a form of low-functioning ASD, whereas cognition in deletion
carriers with ASD is mostly within the normal range. These
results are in line with studies highlighting the potential role of
the CNVs in the speciﬁc patterns of autistic symptoms (46).
For example, there is a long-standing debate on whether ASD
and speciﬁc language impairment arise from similar genetic
bases (47). This study demonstrates that the same genomic
region predisposing to ASD may or may not have a deleterious
effect on structural language depending on the nature of the
mutation. This dissociation between phenotypes observed in
reciprocal CNVs is also corroborated by a recent study
demonstrating that deletions, but not duplications, encom-
passing ASD genes are primarily associated with impairments
in language domains (46).
Special isolated skills and cognitive strengths are also
features deﬁning subgroups of ASD (48). The 16p11.2 dupli-
cation proﬁle is reminiscent of enhanced memory skills also
reported in ASD (49,50) and may represent the ﬁrst example of
an ASD-related genetic predisposition leading to speciﬁc
cognitive strengths compared with control subjects with the
same IQ. The absence of any speciﬁc impairment beyond the
IQ shortfall in duplication carriers at risk for schizophrenia
echoes the nonspeciﬁc cognitive deﬁcit pattern observed in
ﬁrst-episode idiopathic schizophrenia (51,52).
Our results also suggest that neuroanatomic structures
previously deﬁned on the basis of their correlation to number
of genomic copies at the 16p11.2 locus (15) are associated with
alterations in measures of language and verbal inhibition. These
ﬁndings dovetail with previously reported structural ﬁndings
positing the insula as a key player in verbal inhibitory processes
(53,54) as well as the superior temporal gyrus and caudate
nucleus, implicated in speciﬁc language impairment (55–57).
However, larger samples are required to replicate these results
and elucidate any speciﬁc association within groups. The
causal relationship between genomic copies, brain structure,
cognition, and behavior also remains unknown.
Increased volume of the caudate has been observed in
individuals who carry FOXP2 mutations, which is one of the
few genetic forms of speciﬁc language impairment studied to
date (58,59). Language deﬁcits observed in deletion carriers
are largely consistent with a previous study by Hanson et al.
(6) reporting phonological deﬁcits in the context of general
language impairment. Other studies reported the presence of
childhood apraxia of speech, although the exact character-
istics of this deﬁcit are unclear (60–62).
The present study aimed at characterizing the effect of the
16p11.2 locus on speciﬁc cognitive domains by adjusting for
the effect of IQ. We are conﬁdent that our ﬁndings apply to a
broad range of IQ with the exception of very low-functioning
participants who were unable to perform these tasks (11% of
deletion carriers and 27% of duplication carriers). It is unlikely
that the exclusion of individuals with low IQ has biased our
results because a much larger study showed that most136 Biological Psychiatry July 15, 2016; 80:129–139 www.sobp.org/jodeletion carriers and duplication carriers have an IQ .55.
The duplication and the deletion have been associated with a
decrease of approximately 16 points and 22 points of IQ,
respectively (7). This ﬁnding suggests that the subgroup of
very low-functioning carriers may be related to the presence of
additional deleterious genetic variants, which are two to three
times more frequent in 16p11.2 duplication carriers compared
with deletion carriers (7). It is unknown whether low-
functioning carriers represent a distinct subgroup with differ-
ent proﬁles. Most of the probands were ascertained for
neurodevelopmental disorders, which may have also biased
our results. However, stratifying groups in proband and non-
proband carriers does not affect any of the results. The low
frequency of schizophrenia is discordant with the association
reported in prior studies (4). This low frequency is likely to be
due in part to the young age of our probands and the fact that
most of the adults were parents, a fact that selects against a
diagnosis of schizophrenia (63). Follow-up of our probands is
required to estimate accurately the risk of schizophrenia in this
population.
In conclusion, this study suggests that cognitive skills may
be modulated by the number of genomic copies at the
16p11.2 locus in humans. Such effects are clouded by the
global decrease in cognitive functioning that affects both
CNVs. The strength of this study lies in the administration of
an extensive cognitive test battery to both CNV carrier groups
and the intrafamilial control subjects; this allowed us to assess
cognitive function precisely relative to each participant’s
global cognitive level. Further research is warranted to eluci-
date the contribution of speciﬁc genes within the 16p11.2
locus by studying the relationship between expression pat-
terns of these genes and cognitive tasks, brain anatomy, and
brain function. These approaches may ultimately elucidate the
molecular mechanisms that affect speciﬁcally phonological,
verbal memory, and inhibition skills based on the number of
genomic copies. A deeper knowledge of the cognitive
strengths and weaknesses of these patients is critical for
developing cognitive support strategies. Careful language
assessment is recommended in deletion carriers, who might
beneﬁt from more emphasis on the use of visuospatial
processes when learning. In contrast, verbal methods may
improve learning strategies in duplication carriers.ACKNOWLEDGMENTS AND DISCLOSURES
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